Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Checkpoint inhibitors blocking CTLA-4 (ipilimumab) and PD-1 (nivolumab, pembrolizumab) have transfigured our cancer treatment paradigm. However, these drugs can induce immune-related adverse events that share clinical and pathological characteristics with immune-mediated diseases. One of the most severe immune-related adverse event observed with an...
Alternative Titles
Full title
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_hal_01607061v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_01607061v1
Other Identifiers
ISSN
1863-2297
E-ISSN
1863-2300
DOI
10.1007/s00281-016-0613-x
